Lancet:肾动脉超声消融治疗难治性高血压效果明显(RADIANCE-HTN TRIO研究)

2021-07-25 MedSci原创 MedSci原创

高血压作为全球最流行的慢性疾病,在世界范围内,约有1/3的成年人口患有高血压病。根据2010年全球流行病学资料显示,全世界约有13.9亿的高血压患者。根据2020我国流行病学资料显示,我国的高血压患病

高血压作为全球最流行的慢性疾病,在世界范围内,约有1/3的成年人口患有高血压病。根据2010年全球流行病学资料显示,全世界约有13.9亿的高血压患者。根据2020我国流行病学资料显示,我国的高血压患病人口约为2.6亿。高血压是许多心脑血管疾病的最主要的危险因素。据资料显示,20 mm Hg收缩压的升高可引起心脏疾病和脑卒中的死亡风险增加1倍;而相反,10 mm Hg的收缩压的下降可带来脑卒中的发生减少41%。通过药物与生活方式的改变,全球平均高血压的控制率不足20%;而在我国,高血压目前的控制率不足20%。这其中除了高血压的知晓率低,也有药物使用和患者依从性的问题。因此,为了更好的补充降压药物的不足和提升高血压的达标率,在过去近20年内,通过微创介入方法进行的肾动脉消融术(Renal denervation, RDN)应运而生。 由于交感神经的整体兴奋水平是人体发生和维持高血压状态最主要的病理生理学因素之一。人类一直在探寻可以有效降低全身交感神经兴奋水平的方法。早在上世纪40年代末,在有效的降压药物尚未问世的年代,欧美一些外科医生已观察到高血压患者普遍具有面色潮红、易激动等交感神经亢奋

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-11-23 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-07-27 freve
  7. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-07-26 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 25 12:26:23 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639820, encodeId=a7c91639820b3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Jul 29 09:26:23 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831252, encodeId=7e2918312526e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 23 04:26:23 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737198, encodeId=70a41e3719858, content=<a href='/topic/show?id=c17a8249897' target=_blank style='color:#2F92EE;'>#肾动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82498, encryptionId=c17a8249897, topicName=肾动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc5934261565, createdName=江川靖瑶, createdTime=Wed Feb 09 11:26:23 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421865, encodeId=4c901421865c9, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597768, encodeId=cb4f159e768dd, content=<a href='/topic/show?id=28986582e02' target=_blank style='color:#2F92EE;'>#消融治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65827, encryptionId=28986582e02, topicName=消融治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f07818523366, createdName=zhishijing, createdTime=Tue Jul 27 14:26:23 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034403, encodeId=627f103440332, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047405, encodeId=8195104e405ae, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 02:26:23 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-07-26 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

EuroIntervention:肾动脉超声消融治疗难治性高血压长期随访结果公布(RADIANCE-HTN SOLO研究)

早期研究表明,射频去肾交感神经术可降低中度高血压患者的血压。我们研究了在不给予降压药物的情况下,一种替代技术——血管内超声肾交感神经消融术是否能降低高血压患者的动态血压。

Neurology:居住环境周围存在垃圾食品店,更容易患特发性颅内高压

居住环境周围存在垃圾食品店,更容易患特发性颅内高压

2018 AHA科学声明:难治性高血压的检测,评估和管理

2018年9月,美国心脏协会(AHA)颁布了新版《难治性高血压检测、评估和管理科学声明》,这是对2008年发布的第一份难治性高血压科学声明的更新,反映了过去十年间发表的新的科学证据。声明的重点内容包括定义的更新、诊断方法和治疗的建议。

CHC2018丨刘蔚教授:难治性高血压药物治疗新认识

编者按:研究表明,难治性高血压临床风险高,需明确诊断和有效的治疗方法。8月2~5日,CHC 2018大会上,卫生部北京医院刘蔚教授针对难治性高血压的药物治疗,发表了自己的新观点,现撷取精彩内容如下。

JAHA:顽固性高血压患者难治性高血压与心血管事件和死亡风险

相比于顽固性非难治性高血压患者,RfHT患者,尤其是根据不受控制的动态血压水平诊断时,发生重大不良CVE和死亡的风险更高。

祝之明:难治性内分泌高血压的微创消融治疗

美国心脏协会(AHA)难治性高血压专家共识指出,继发性高血压是难治性高血压的主要原因之一,而在继发性高血压中,内分泌性疾病特别是肾上腺疾病引起的高血压占据相当大的比重。